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Abstract
Background: Most accrued evidence regarding prophylactic octreotide for a pancreatoduodenectomy
(PD) predates the advent of the International Study Group of Pancreatic Fistula (ISGPF) classification
system for a post-operative pancreatic fistula (POPF), and its efficacy in the setting of high POPF risk is
unknown. The Fistula Risk Score (FRS) predicts the risk and impact of a clinically relevant (CR)-POPF and
can be useful in assessing the impact of octreotide in scenarios of risk.
Methods: From 2001–2013, 1018 PDs were performed at four institutions, with octreotide administered
at the surgeon's discretion. The FRS was used to analyse the occurrence and burden of POPF across
various risk scenarios.
Results: Overall, 391 patients (38.4%) received octreotide. A CR-POPF occurred more often when
octreotide was used (21.0% versus 7.0%; P < 0.001), especially when there was advanced FRS risk.
Octreotide administration also correlated with an increased hospital stay (mean: 13 versus 11 days;
P < 0.001). Regression analysis, controlling for FRS risk, demonstrated that octreotide increases the risk
for CR-POPF development.
Conclusion: This multi-institutional study, using ISGPF criteria, evaluates POPF development across the
entire risk spectrum. Octreotide appears to confer no benefit in preventing a CR-POPF, and may even
potentiate CR-POPF development in the presence of risk factors. This analysis suggests octreotide
should not be utilized as a POPF mitigation strategy.
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Introduction
A post-operative pancreatic fistula (POPF) and the clinical con-
sequences of its sequelae after a pancreatoduodenectomy (PD)
have been well documented in the literature.1–4 Numerous miti-
gation strategies for a POPF are available to the surgeon, including
the use of somatostatin analogues, such as octreotide,5–8 with the
putative effect of inhibiting both gastric and pancreatic exocrine
secretion.9–12
Early biochemical investigation focused on somatostatin’s
ability to ameliorate pancreatitis through the inhibition of exo-
crine function;13,14 in spite of inconclusive findings, other studies
suggested a benefit for reducing the incidence of post-operative
complications.15 Octreotide is a potent inhibitor of pancreatic
exocrine secretion, and as pancreatic enzyme secretion is pro-
posed as a driver of fistulae, some advocate its use as a prophylac-
tic measure.5,16
In fact, the use of octreotide during a pancreatic resection has
been studied extensively, even to the level of eight high-accrual
(> 100 cases), randomized-controlled trials.5–8,17–20 In spite of
extensive scrutiny, octreotide’s efficacy remains controversial.
Büchler’s landmark study showed that octreotide was beneficial
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for reducing the rate of fistulae; however, it had the following
limitations: (i) it failed to delineate between biochemical fistulae
and those we now consider clinically relevant; (ii) it analysed both
PD and other forms of pancreatic resection together; and (iii) the
risk-adjustment process was limited only to disease pathology.5
The analysis did not account for other currently validated risk
factors for the development of a clinically relevant (CR)-POPF
such as soft gland parenchyma, small pancreatic duct size and
elevated intra-operative blood loss, which contribute to the Fistula
Risk Score (FRS).21,22
In contrast, studies by both Yeo et al. and Sarr et al. failed to
demonstrate clinical and economic value to somatostatin ana-
logues for post-operative pancreatic fistula mitigation.18,19 Impor-
tantly, all eight of these major studies are now over a decade old
and therefore predated the establishment of the International
Study Group of Pancreatic Fistula (ISPGF) fistula classification
framework, which established a clear dichotomy between a bio-
chemical and clinically-relevant fistula.2 One study, published
since the advent of the ISGPF schema, argued for the selective use
of prophylactic octreotide, citing a lack of both clinical effect and
cost-containment in low-risk scenarios;23 however, the study
occurred before the development of the FRS and it was a single-
institution experience.
This large, multi-centre experience aimed to examine the effi-
cacy of prophylactic octreotide for PD using ISGPF definitions for
a clinically relevant fistula. In addition, the FRS, a highly validated
tool for predicting the occurrence of a CR-POPF, was used for risk
adjustment.24
Methods
In accordance with guidelines for human subjects’ research, this
study was approved by the Institutional Review Board (IRB) at the
Hospital of University of Pennsylvania. Records for consecutive
patients who underwent a proximal pancreatectomy for all indi-
cations were reviewed from prospectively collected databases at
four high-volume, academic pancreatic surgical practices (six sur-
geons), between 2001 and 2013. Two hundred and twenty-seven of
the patients have previously been described in a single-centre
review of octreotide use.23
Surgical approach
All procedures were performed with duct-to-mucosa
pancreaticojejunostomy reconstruction; alternative methods of
reconstruction (PG) were excluded from this study. Anastomotic
stents and drains were used at the surgeon’s discretion. Drain
amylase levels were recorded on post-operative day (POD) 3 and,
in the case of multiple drains, the highest concentration of drain
amylase was used to ascertain whether at least a biochemical
(Grade A) POPF had occurred. Drains were removed most often
after tolerance of a regular diet (POD 5–7), but at the surgeon’s
discretion. Early drain removal, based on drain amylase levels at
POD 3 or earlier, was not practiced in this series.
When prophylactic octreotide [Sandostatin LAR (Novartis
Pharma, Novartis AG, Basel, Switzerland) 150 μg subcutaneously]
was used, it was initiated intra-operatively by the surgeon at the
point of construction of the pancreaticojejunal anastomosis and
continued post-operatively every 8 h for 7 days.
Data collection and fistula classification
Outcomes were measured up to 90 days post-operation, including
pancreatic fistula occurrence,mortality, duration of stay and read-
mission. Complications were assessed using the Modified Accor-
dion Severity Grading System.25 Previously validated risk factors
for the development of a CR-POPF21,22 were recorded for each
patient. These pre- and intra-operative variables include pancre-
atic parenchyma texture, disease pathology (high risk = anything
other than pancreatic adenocarcinoma or pancreatitis), duct
diameter (measured intra-operatively) and intra-operative blood
loss. Each risk factor is associated with a weighted score in accord-
ance with odds ratios (ORs) established by Callery et al.
(Table 1).22 The relative value of each risk factor was summated to
calculate a FRS (0–10) for each individual patient. FRSs were then
discretized and allocated to one of four risk zones: negligible risk
(0 points), low risk (1–2 points), moderate risk (3–6 points) and
high risk (7–10 points). Each zone reflects distinct tiers of
CR-POPF risk based on the aggregate of weighted endogenous
and operative risk factors.
Fistula severity was assigned in accordance with the tenants of
the International Study Group of Pancreatic Fistula (ISGPF) clas-
sification framework;2 individual grades were computed using the
PancreasClub calculator.26 The ISGPFdefined the threshold for the
occurrence of POPF as drainage from an operatively placed drain
Table 1 Fistula Risk Score for the prediction of clinically-relevant
fistula (CR-POPF) after pancreatoduodenectomy
Risk factor Parameter Points
Gland texture Firm 0
Soft 2
Pathology Pancreatic adenocarcinoma
or pancreatitis
0
Ampullary, duodenal,
cystic, islet cell, etc.
1
Pancreatic
duct
diameter
≥ 5 mm 0
4 mm 1
3 mm 2
2 mm 3
≤ 1 mm 4
Intra-operative
blood loss
≤ 400 ml 0
401–700 ml 1
701–1000 ml 2
>1000 ml 3
Total 0 to 10 points
From Callery et al. JACS, 2013.
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(or subsequently placed percutaneous drain), on or after POD 3,
with an amylase concentration greater than three times the upper
limit of normal serum amylase (> 300 IU/l). When POPFs
occurred in this series, they were segregated into two categories
(biochemical or clinically-relevant) and three grades (A, B or C).
Biochemical fistulae (Grade A) are transient and asymptomatic,
characterized only by elevated drain amylase levels and they have
no significant clinical sequelae.2,27 In contrast, CR-POPFs (Grades
B andC) aremoremorbid anddemonstrate deviation fromnormal
clinical management. Grade B fistulae are symptomatic fistulae,
which require diagnostic evaluation and therapeuticmanagement.
The spectrum of treatment measures include: antibiotic therapy,
therapeutic (non-prophylactic) octreotide, supplemental nutri-
tion (TPN), maintenance of operatively placed drains > 21 days,
additional percutaneous drainage, or endoscopic/interventional
radiology procedures.2 Grade C fistulae manifest a significant
deviation from the normal clinical pathway, in the form of an
operative intervention under general anaesthesia. These particu-
larly severe fistulae can also lead to sepsis, organ failure or death.2
Study endpoint
The primary endpoint of this study was to test the null hypothesis
that the administration of octreotide does not significantly reduce
the occurrence of CR-POPF after a PD. Secondary endpoints
included investigating the effects of octreotide on hospital dura-
tion of stay, major morbidity (Accordion Grades ≥ 3) and
mortality.
Statistical analysis
Comparative analyses between cohorts were conducted using χ2
or Fisher’s exact tests for categorical variables and Student’s t-test
or Wilcoxon’s signed-rank test for continuous variables. P-values
less than 0.05 were considered statistically significant. A
multivariable regression was performed adjusting for endogenous
and intra-operative CR-POPF risk factors. All candidate predic-
tive variables were entered via forward stepwise regression
(P < 0.05 for entry) and those variables demonstrating no inde-
pendent association (P > 0.10) with the outcome of a CR-POPF
were removed. All statistical computations were performed utiliz-
ing IBM SPSS, version 21 (SPSS Inc., Chicago, IL, USA).
Results
Patients, octreotide use and general outcomes
One thousand and eighteen consecutive PDs were performed by
six surgeons (range: 5–307) at four institutions (range: 130–445).
Trans-anastomotic stents were used in 557 (54.7%) patients, with
the internal variety selected 80.6% (n = 449) of the time. One or
more Blake drains were placed adjacent to the pancreaticojejunal
anastomosis in 886 (87.0%) patients. Three hundred and ninety-
one patients (38.4%) received prophylactic octreotide. One
surgeon (n = 136) always applied octreotide, two surgeons
(n = 307, 86) never used it and three employed it selectively
(octreotide: n = 155, 97, 3; no octreotide: n = 139, 93, 2).
The utilization of octreotide was distributed unevenly across
the FRS risk zones: negligible – 9.2%; low – 23.8%; moderate –
61.9%; and high – 5.1%. By comparison, the breakdown of the
no-octreotide cohort was: negligible – 18.5%; low – 32.4%; mod-
erate – 42.7%; high – 6.4%. Table 2 shows the frequency of
octreotide’s administration within each FRS risk zone.
In the overall series, any Accordion complication occurred in
63.5% of the patients; the incidence of Accordion severity grades
≥ 3 was 22.0%. The median duration of stay for the entire
study population was 8 days [interquartile range (IQR) 5.0].
Reoperation was necessary in 6.5% of the patients and the 90-day
readmission rate was 17.8%. There were 24 (2.4%) mortalities
within 90 days.
Risk factors for a CR-POPF
High-risk pathology was encountered more frequently in the
octreotide cohort (P < 0.001). Additionally, soft gland texture was
evident more often in the octreotide cohort (58.5% vs. 41.5%;
P < 0.001); however, there were no significant differences in terms
of pancreatic duct diameter and intra-operative blood loss
(Table 2).
Fistula occurrence
Overall, 245 patients developed a POPF (24.1%), of which, 126
were clinically relevant (12.4%; Grade B – 10.1%; and Grade C –
2.3%). The number of FRS risk factors present in any given
patient correlated strongly with CR-POPF occurrence: none – 0%;
one – 5.6%; two – 10.4%; three – 22.9%; and four – 30.3%. The
risk factor most strongly associated with CR-POPF occurrence
was soft gland texture (20.4%; P < 0.001), closely followed by
high-risk pathology (19.5%; P < 0.001), duct diameter ≤ 4 mm
(16.4%; P < 0.001) and intra-operative blood loss > 400 ml
(16.3%; P = 0.023). The mean, median and mode of the FRS were
3.10, 3.00 and 1.00, respectively.
Comparison of the two treatment cohorts revealed octreotide
was associated with higher rates of an overall POPF (28.1% vs.
21.5%; P = 0.017) (Table 3). Additionally, a CR-POPF occurred
more frequently in patients receiving octreotide (21.0% versus
7.0%; P < 0.001). In contrast, the rate of a biochemical fistula was
significantly less when octreotide was administered (7.2% versus
14.5%; P < 0.001).
Patients in the octreotide cohort experienced higher rates of
CR-POPF in the presence of each FRS risk factor (Table 4); this
pattern continued when analysing CR-POPF occurrence using the
calculated FRS (Fig. 1). Patients receiving octreotide experienced
higher rates of CR-POPF across each FRS Risk Zone (Fig. 2).
Notably, when octreotide was not employed, fistula occurrence
increased linearly with escalating risk; whereas, there was an expo-
nential increase in CR-POPF rates across the zones when
octreotide was used.
Forward stepwise regression revealed predictors of CR-POPF:
the use of octreotide (OR: 2.6; P < 0.001), a lack of routine drain
placement (OR: 2.3; P = 0.003) and increasing FRS (OR: 1.5 per
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unit increase; P < 0.001) (Fig. 3 and Table 5). The use of octreo-
tide correlated with the increased incidence of CR-POPF, but it
also corresponded to lower rates of biochemical fistula. In the
absence of octreotide, Grade A fistulae occurred more frequently
with escalating risk; however, when octreotide was administered,
rates of biochemical fistula levelled out (Fig. 4).
Other outcomes
Overall morbidity was not significantly different between the two
cohorts; however, complications with an Accordion severity grade
≥ 3 occurred more frequently in the octreotide cohort (28.9%
versus 17.7%; P < 0.001). Patients in both treatment groups with
negligible and low fistula risk had similar rates of Accordion sever-
ity grades ≥ 3 (octreotide: 17.8% versus control: 15.4%;
P = 0.519); yet, differences arise among moderate- and high-risk
patients, where octreotide correlated with higher rates of these
more morbid complications (34.4% versus 20.1%; P < 0.001).
The post-operative course also revealed octreotide to be asso-
ciated with higher rates of re-operation, peri-operative blood
transfusion, percutaneous drain placement, TPN supplementa-
tion and Intensive Care Unit transfer (Table 3). Adjusting for
fistula risk explained some of these differences, but octreotide still
trended with higher rates across the risk spectrum (percutaneous
drain placement, peri-operative transfusion: P < 0.001; TPN:
P = 0.015; ICU transfer: 0.031; re-operation: P = 0.111).
The median duration of stay was significantly greater for
patients receiving prophylactic octreotide [9 (IQR 6.0) versus
8 days (IQR 4.0); P < 0.001], yet 90-day mortality and readmis-
sion were not different between the two treatment cohorts.
Discussion
This study shows that prophylactic octreotide is strongly associ-
ated with a greater incidence of a CR-POPF, Accordion complica-
tion severity grades ≥ 3, re-operation and an increased duration of
hospital stay. In particular, the study found octreotide to correlate
with significantly higher rates of a CR-POPF among patients with
moderate and high fistula risk – the very cases with which many
would expect the greatest efficacy. The occurrence of a CR-POPF
was 15.5% and 47.5% greater among moderate- and high-risk
patients, respectively. This disparity revealed an exponential rela-
tionship between escalating risk and CR-POPF occurrence among
patients in the octreotide treatment cohort. In contrast, CR-POPF
incidence increased linearly with risk in the cohort not receiving
octreotide.
These associations are similar to those found by Lowy et al.,
who concluded that routine use of octreotide after PD should not
be recommended.17 In that prospective study, 110 patients were
randomized to prophylactic octreotide or no further treatment. In
spite of pre-dating the advent of the ISGPF fistula classification
Table 2 Endogenous and intra-operative clinically relevant-post-operative pancreatic fistula (CR-POPF) risk factors and distribution of
fistula risk
n (%) or mean (SD) Overall No octreotide Octreotide P-valuea
Pathology
Pancreatic adenocarcinoma 407 (40.0) 277 (44.2) 130 (33.2) <0.001
Cystic neoplasm 151 (14.8) 91 (14.5) 60 (15.3) 0.717
Pancreatitis 130 (12.8) 94 (15.0) 36 (9.2) 0.007
Ampullary carcinoma 110 (10.8) 61 (9.7) 49 (12.5) 0.161
Benign lesion 51 (5.0) 12 (1.9) 39 (10.0) <0.001
Cholangiocarcinoma 48 (4.7) 26 (4.1) 22 (5.6) 0.279
Duodenal Carcinoma 39 (3.8) 18 (2.9) 21 (5.4) 0.043
Other lesions 39 (3.8) 28 (4.5) 11 (2.8) 0.182
Islet cell tumour 35 (3.4) 17 (2.7) 18 (4.6) 0.107
Metastatic lesion 8 (0.8) 3 (0.5) 5 (1.3) 0.272
Soft gland texture 514 (50.5) 260 (41.5) 367 (58.5) <0.001
Duct size (mm) 4.2 (1.9) 4.2 (1.8) 4.1 (2.0) 0.553
Intra-operative blood loss (ml) 397 (578) 409 (694) 380 (313) 0.440
Fistula risk zone
Negligible 152 (14.9) 116 (76.3)b 36 (23.7)b <0.001
Low 296 (29.1) 203 (68.6) 93 (31.4) 0.003
Moderate 510 (50.1) 268 (52.5) 242 (47.5) <0.001
High 60 (5.9) 40 (66.7) 20 (33.3) 0.405
aComparing treatment with octreotide versus no octreotide.
bPercentage reflects contribution to the total number of patients in the overall series within each risk zone.
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system, this study delineated between biochemical and clinically
relevant fistulae. Biochemical leaks were defined as elevated drain-
amylase (> 2.5 normal upper limit of normal for serum amylase)
after POD 3 – very similar to the same ISGPF definition. Clinically
significant fistulae met the specifications for a biochemical fistula,
but also had to be accompanied by fever, leukocytosis, sepsis or the
need for percutaneous drainage. Using these definitions, they
found the rate of a clinically significant fistula to be lower in the
absence of octreotide (6% versus 12%; P = 0.23).17 The study
also found no significant differences between the treatment
groups in terms of overall morbidity, duration of hospital stay and
mortality.
Several years later, a study by Yeo et al. corroborated the find-
ings of Lowy et al. That single-centre study randomized 211
patients to either prophylactic octreotide or saline. Pancreatic fis-
tulae were defined as drainage of amylase-rich fluid > 3 times the
upper limit of normal serum after POD 10, or pancreatic
anastomotic disruption observed from radiographical imaging.18
The rates of pancreatic fistula were 9% in the control group com-
pared to 11% in the cohort receiving octreotide. Overall morbid-
ity was also greater in the octreotide group (40% versus 34%),
along with mortality (1% versus 0%); the median duration of stay
was equivalent between treatments. A cost analysis also concluded
that the elimination of octreotide would be beneficial.
Contrary to the findings of this present study, four randomized,
controlled, multicentre studies from Europe, all almost 20 years
old, found octreotide to be beneficial for reducing the occurrence
of a fistula;5–8 in spite of the congruence of their arguments, each
study has been criticized for significant limitations.28 First, the
liberal definition for a fistula in each of these studies aligns with
what is now considered the threshold for a biochemical fistula. As
biochemical leaks are asymptomatic and resolve without sequelae,
it is necessary to classify a pancreatic fistula into subcategories that
speak to their clinical significance. The results of this present study
demonstrated that octreotide was associated with significantly
lower rates of a biochemical fistula, whereas also strongly corre-
lating with elevated rates of CR-POPF. In a smaller sample size,
these opposing trends could possibly cancel each other out and
make octreotide appear to have no effect on overall pancreatic
fistula occurrence.
A recent Cochrane Collaboration addressed the issue of fistula
nomenclature while attempting to ascertain the efficacy of soma-
tostatin analogues; however, the analysis could only find three
published randomized-controlled studies in which clinically rel-
evant fistulae were distinguished from biochemical leaks, and only
one of them used the ISGPF construct.29 In two of the three
Table 3 Post-operative outcomes
n (%) or median
(interquartile range)
Overall
No
octreotide
Octreotide P-value
Patients 627 (61.6) 391 (38.4) –
POPF 135 (21.5) 110 (28.1) 0.017
CR-POPF 44 (7.0) 82 (21.0) <0.001
ISGPF classification
Grade A 91 (14.5) 28 (7.2) <0.001
Grade B 36 (5.7) 67 (17.1) <0.001
Grade C 8 (1.3) 15 (3.8) 0.007
Any complication, N (%) 395 (63.0) 251 (64.2) 0.700
Accordion severity
grade ≥ 3, N (%)
111 (17.7) 113 (28.9) <0.001
Performance measures
Hospital transfusion 144 (23.0) 155 (39.6) <0.001
Percutaneous drain
placement
24 (3.8) 55 (14.1) <0.001
TPN 121 (19.3) 106 (27.1) 0.004
Re-operation 33 (5.3) 33 (8.4) 0.045
ICU transfer 45 (7.2) 46 (11.8) 0.013
Mortality – 90 days 13 (2.1) 11 (2.8) 0.525
Readmission –
90 days
106 (16.9) 75 (19.2) 0.356
Duration of stay (days) 8 (7–11) 9 (8–14) <0.001
PDOD, post-operative pancreatic fistula; CR-POPF, clinically relevant-
post-operative pancreatic fistula; ISGPF, International Study Group of
Pancreatic Fistula; TPN, total parenteral nutrition; ICU, intensive care
unit.
Table 4 Clinically relevant fistula occurrence in the presence of
fistula risk factors
FRS risk factor No octreotide Octreotide P-value
CR-POPF,
n (%)
CR-POPF,
n (%)
Patients 627 (61.6) 391 (38.4) –
High-risk pathologya 27 (10.5) 67 (29.8) <0.001
Soft gland texture 32 (12.3) 73 (28.7) <0.001
Duct size risk factor (≤
4 mm)
35 (9.2) 68 (27.2) <0.001
Duct size
≥ 5 mm 9 (3.6) 14 (9.9) 0.011
4 mm 14 (9.7) 14 (19.4) 0.045
3 mm 6 (4.8) 25 (23.4) <0.001
2 mm 13 (14.6) 25 (39.7) 0.001
≤1 mm 2 (10.0) 4 (50.0) 0.038
Blood loss risk factor
(> 400 ml)
15 (9.4) 28 (27.2) <0.001
Intra-operative blood loss
≤400 ml 29 (6.2) 54 (18.8) <0.001
401–700 ml 10 (10.3) 16 (23.2) 0.024
701–1000 ml 3 (7.7) 6 (28.6) 0.054
>1000 ml 2 (8.3) 6 (46.2) 0.013
aAny pathology exclusive of pancreatic adenocarcinoma or pancreatitis.
CR-POPF, clinically relevant-post-operative pancreatic fistula; FRS,
Fistula Risk Score.
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Figure 1 Surgeon octreotide use and their clinically relevant-post-
operative pancreatic fistula (CR-POPF) probabilities across the
spectrum of fistula risk
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studies, the rates of clinically relevant fistulae were higher in the
octreotide cohort.30,31 The third study, conducted by Gouillat
et al.,32 found octreotide to lower the incidence of clinically rel-
evant fistulae, yet it has been cited for a high risk of bias.29 An
additional limitation of that particular study was its modest
overall sample size (n = 75).
Another shortcoming of these studies was that all of the trials
included many types of pancreatic resections.5–8 Risk factors for a
clinically relevant fistula vary depending on the type of pancreatic
resection and an inclusive analysis could distort the interpretation
of fistula outcomes for a PD.3 The study by Montorsi et al. was the
only one to conduct subset analyses based on the type of pancrea-
tectomy. Not surprisingly, the frequency of fistula varied between
procedures and differences between treatments became non-
significant for a PD (control: 14.9%; octreotide: 10.5%), whereas
octreotide was associated with fewer fistulae after a distal pancrea-
tectomy (6.0% versus 21.2%) and enucleations (0% versus
57.1%).7
The final major limitation of the studies that support octreotide
use, and also many of the recent retrospective studies,16,33 is the
absence of a comprehensive risk adjustment process. Most of the
early literature was largely limited to univariate analyses, and even
recent retrospective works have excluded highly validated risk
factors, such as soft gland and duct size, when conducting
multivariable testing.16 Our study addressed this issue by utilizing
the externally validated FRS, which has shown a strong capacity to
predict CR-POPFs;24 this metric adjusted for endogenous and
operative fistula risk when comparing the clinically relevant out-
comes between treatment cohorts.
Biological explanations for the results of our study can be found
throughout the bench science and translational literature. The
foremost factor mentioned is the effect of octreotide on
splanchnic blood flow; multiple studies have correlated octreotide
with decreased pancreatic perfusion and gastroduodenal mucosal
blood flow.10,11,34–39 This regionalized ischaemia could limit or
impair wound healing at the site of the anastomosis.40 Many of
these previous studies were conducted with intravenous, rather
than subcutaneous, administration of somatostatin and its ana-
logues; however, a study by Eriksson et al. demonstrated that both
intravenous and subcutaneous administration of a long-acting
somatostatin analogue decreased splanchnic blood flow by
20–25% in human subjects.41
Second, octreotide has been shown to suppress the secretion of
anabolic and tropic hormones such as pituitary growth hormone
(GH), insulin-like growth factor 1 (IGF-1) and epidermal growth
factor (EGF), all of which facilitate the wound-healing
process.9,42–44 An earlier work by Konturek et al. demonstrated that
EGF inhibition causes a delay in the healing of gastrointestinal
ulcers; the study attributed these findings to the important
mitogenic effects of EGF.45 A study by Waddell et al. even com-
pared the impact octreotide has on wound healing to that of
immunosuppressive steroids.46
Additionally, Jenkins et al. observed subcutaneous administra-
tion of octreotide to decrease the volume of pancreatic juice, while
also causing large fluctuations in enzyme concentration. That
study concluded that a low volume of pancreatic juice with high
enzyme concentrations might delay fistula closure.47 The answer
for octreotide’s association with higher rates of CR-POPF is
almost certainly multifactorial and cannot be conclusively defined
by a single physiological mechanism.
There are several limitations to this present study, such as the
absence of a randomization process with the administration of
octreotide; it was administered at the surgeon’s discretion. This
first limitation was addressed through the use of the FRS to
compare patients with similar risk profiles for CR-POPF develop-
ment. An additional limitation was that octreotide usage was not
normally distributed between surgeons. To minimize this poten-
tial source of bias, the multivariate model considered other poten-
tial confounding factors such as surgeon years of experience, the
use of trans-anastomotic stents and routine intraperitoneal drain
placement.
Conclusion
In this assessment of octreotide for a PD, the largest to date, it
appears that when looking through the prism of risk adjustment,
not only is octreotide ineffective at mitigating a CR-POPF, it
might actually potentiate risk. To conclude, these data suggest that
octreotide should not be used as a fistula mitigation strategy.
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